4.6 Article

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Related references

Note: Only part of the references are listed.
Review Oncology

Myelodysplastic Syndromes: A New Decade

Virginia O. Volpe et al.

Summary: Myelodysplastic syndromes (MDS) is a group of heterogeneous clonal hematopoietic stem cell disorders with an increasing incidence rate with age. Risk stratification, prognosis, survival, and AML transformation in MDS depend largely on the revised International Prognostic Scoring System and molecular genetic testing. Treatment varies based on disease severity, with low-risk MDS aimed at alleviating anemia symptoms and high-risk MDS requiring prompt initiation of hypomethylating agents. Allogeneic stem cell transplant may be the only potential cure for high-risk MDS.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Review Medicine, Research & Experimental

Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes

Amit Verma et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Article Medicine, General & Internal

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Oncology

Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS

Rami S. Komrokji

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)